MAUL was the first organization to bring ARVs to Africa during the late 1990s.

  • More than 205,000 people living with HIV/AIDS have received ARVs as a result of MAUL’s work with 11 PEPFAR/CDC-supported Implementing Partners in more than 190 sites across Uganda.
  • With no stock-outs of ARVs in the last 10 years, MAUL’s Implementing Partners now have more time to focus on their core business.
  • More than 400 health workers across Uganda have been trained by MAUL on effective supply chain management practices.
  • MAUL was instrumental in driving down the price of ARVs through a systematic nationwide switch from branded to generic ARVs, which saved over US$100 million between 2007 and 2012.
  • MAUL has executed total procurements valued at US$ 152 million.
  • MAUL-supported Implementing Partners were amongst the first to access US FDA-approved generic ARVs within PEPFAR-supported countries.
  • MAUL supported the expansion of laboratory infrastructure and services in 50 health facilities.
  • In serving our broad client base, MAUL has established a strong network of more than 200 reliable partners and suppliers across the globe.
  • MAUL distributes an average US$36 million per year reaching more than 190 health facilities across 65 districts.